news
Leukine® is beneficial to patients with mild-to-moderate Alzheimer’s, finds study
In a Phase II trial, Leukine® (sargramostim) significantly reduced biomarkers of neurodegeneration and improved cognitive function.
List view / Grid view
Alzheimer’s disease
news
Salbutamol significantly increases cerebral perfusion in proof-of-concept trial
In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease.
news
XPro1595 significantly improves neurodegeneration in AD trial
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
news
Noncommunicable diseases are leading cause of death and disability worldwide, says WHO
Alzheimer’s and diabetes enter the top ten global causes of death for the first time, while HIV/AIDS and tuberculosis deaths fall, according to the WHO’s 2019 Global Health Estimates.
article
Could newborn stem cells revolutionise cell therapies?
In this article, Dr Jaime Shamonki, Generate Life Science’s CMO, discusses how newborn stem cells derived from umbilical cord tissue could make mesenchymal stem cells less expensive and variable to produce.
news
COVID-19 therapeutics to rely on large-scale biomanufacturing reactors, report says
A new report has found that if COVID-19 biologics are approved, it could apply pressure to the global biomanufacturing capacity.
news
Smart biomaterial drug delivery system could improve CNS injury recovery
The implanted biomaterial drug delivery system releases methylprednisolone and reduces inflammation, promoting central nervous system (CNS) repair.
news
Novel anti-amyloid drug BAN2401 enters Phase III trial in Alzheimer’s patients
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
news
Rotigotine improves cognitive function in Alzheimer’s patients
In a study of 94 patients with mild-to-moderate Alzheimer’s disease, rotigotine improved frontal lobe executive function and enabled patients to independently perform daily activities.
news
Nilvadipine and related drugs could slow Alzheimer’s progression
Researchers have shown that Nilvadipine can slow the rate of cognitive decline in very early- and early-stage Alzheimer’s patients and have received funding to develop improved versions.
news
Solanezumab fails to meet primary endpoint of Phase II/III Alzheimer’s trial
The developers have announced solanezumab failed to show disease-modifying properties against dominantly inherited Alzheimer's disease (DIAD).
news
Patents for NLRP3 inflammasome-inhibiting compounds granted in US and Europe
Inflazome has announced that the US and EU will grant patents to their NLRP3 inflammasome inhibiting compounds.
news
Allergan to reportedly settle Alzheimer’s therapy lawsuit for $750m
Allergen is to reportedly settle a class-action lawsuit which alleges that it worked to delay generic competition for Alzheimer’s disease therapy Namenda.
news
Early Alzheimer’s disease treatment meets trial primary endpoints
Aducanumab, an Alzheimer's disease treatment, will be submitted as part of a Biologics License Application after meeting clinical trial primary endpoints.
news
New breakthrough can effectively deliver medications into the brain
Scientists have found a way to effectively transport medication into the brain which could lead to improved treatments for neurological and neurodegenerative diseases.
